NO20073490L - Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav - Google Patents
Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser deravInfo
- Publication number
- NO20073490L NO20073490L NO20073490A NO20073490A NO20073490L NO 20073490 L NO20073490 L NO 20073490L NO 20073490 A NO20073490 A NO 20073490A NO 20073490 A NO20073490 A NO 20073490A NO 20073490 L NO20073490 L NO 20073490L
- Authority
- NO
- Norway
- Prior art keywords
- antibiotic
- factors
- compositions
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000192125 Firmicutes Species 0.000 abstract 1
- 241000606768 Haemophilus influenzae Species 0.000 abstract 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 abstract 1
- 241000906785 Microbispora sp. Species 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229960003085 meticillin Drugs 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Det beskrives en antibiotisk substans av mikrobiell opprinnelse, vilkårlig benevnt antibiotikum 107891 som produseres ved fermentering av Microbispora sp. ATCC PTA-5024, farmasøytisk akseptable salter og sammensetninger derav, og deres anvendelse som et antibakterielt middel som har en inhibitorisk aktivitet versus mottakelige mikrober. Antibiotikum 107891, som er et kompleks som omfatter to faktorer, benevnt faktor Al og faktor A2, har en peptidstruktur som inneholder lantionin og metyllantionin som bestanddeler og som er typiske karakteristika for antibiotika av lantibiotikagruppen. Antibiotikum 107891 og dets faktorer Al og A2 viser en god antibakteriell aktivitet mot Grampositive bakterier inkluderende meticillinresistente og vancomycinresistente stammer, og er også aktiv mot noen Gramnegative bakterier så som M. catharralis, Neisseria-arter og H. influenzae og Mycobacteria.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/045,628 US7351687B2 (en) | 2003-07-18 | 2005-01-26 | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
PCT/US2005/002733 WO2006080920A1 (en) | 2005-01-26 | 2005-01-27 | Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20073490L true NO20073490L (no) | 2007-08-07 |
Family
ID=36740829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20073490A NO20073490L (no) | 2005-01-26 | 2007-07-05 | Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav |
Country Status (26)
Country | Link |
---|---|
US (1) | US7351687B2 (no) |
EP (2) | EP2402366A1 (no) |
JP (1) | JP4191238B2 (no) |
KR (1) | KR100896826B1 (no) |
CN (1) | CN101189252B (no) |
AU (1) | AU2005326149C1 (no) |
BR (1) | BRPI0519942A2 (no) |
CA (1) | CA2593801A1 (no) |
CY (1) | CY1113030T1 (no) |
DK (1) | DK1848731T3 (no) |
EA (1) | EA016608B1 (no) |
ES (1) | ES2387557T3 (no) |
HR (1) | HRP20120634T1 (no) |
IL (1) | IL184377A0 (no) |
MA (1) | MA29237B1 (no) |
MX (1) | MX2007009059A (no) |
NO (1) | NO20073490L (no) |
NZ (1) | NZ556368A (no) |
PL (1) | PL1848731T3 (no) |
PT (1) | PT1848731E (no) |
RS (1) | RS52427B (no) |
SI (1) | SI1848731T1 (no) |
TN (1) | TNSN07286A1 (no) |
UA (1) | UA87548C2 (no) |
WO (1) | WO2006080920A1 (no) |
ZA (1) | ZA200705495B (no) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0600928D0 (en) | 2006-01-17 | 2006-02-22 | Novacta Biosystems Ltd | Improvements relating to lantibiotics |
GB0714029D0 (en) | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | Lantibiotic-based compounds having antimicrobial activity |
GB0714030D0 (en) | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | The use of type-B lantibiotic-based compounds having antimicrobial activity |
JP5719312B2 (ja) | 2009-01-14 | 2015-05-13 | ノヴァクタ バイオシステムズ リミティッド | デオキシアクタガルジン誘導体 |
AU2010212183B2 (en) | 2009-02-04 | 2014-07-10 | Novacta Biosystems Limited | Actagardine derivatives |
GB201001688D0 (en) | 2010-02-02 | 2010-03-17 | Novacta Biosystems Ltd | Compounds |
GB201013513D0 (en) | 2010-08-11 | 2010-09-22 | Novacta Biosystems Ltd | Formulations |
US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59198982A (ja) | 1983-04-28 | 1984-11-10 | Meiji Seika Kaisha Ltd | 新抗生物質sf−2240物質およびその製造法 |
EP0592835A3 (en) | 1992-09-23 | 1995-03-15 | Bristol Myers Squibb Co | Antibiotics of type BU-4803T. |
US6551591B1 (en) | 2001-09-07 | 2003-04-22 | Essential Therapeutics, Inc. | Antibiotics from microbispora |
US6551581B1 (en) | 2001-12-27 | 2003-04-22 | Avon Products, Inc. | Methods for improving the aesthetic appearance of skin and hair |
US7307057B2 (en) * | 2003-07-18 | 2007-12-11 | Naicons S.C.A.R.L. | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
KR100892655B1 (ko) * | 2005-01-12 | 2009-04-15 | 비큐론 파마세티컬스 인코포레이티드 | 항생제 107891, 그의 팩터 a1 및 a2, 제약학상허용되는 염 및 조성물, 및 그의 용도 |
CN101098707B (zh) * | 2005-01-12 | 2011-11-30 | 森帝奈拉医药品公司 | 抗生素107891、其因子a1和a2、可药用盐和组合物及其用途 |
WO2006075988A1 (en) * | 2005-01-12 | 2006-07-20 | Vicuron Pharmaceuticals Inc. | Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof |
-
2005
- 2005-01-26 US US11/045,628 patent/US7351687B2/en not_active Expired - Lifetime
- 2005-01-27 ES ES05712250T patent/ES2387557T3/es active Active
- 2005-01-27 EA EA200701384A patent/EA016608B1/ru not_active IP Right Cessation
- 2005-01-27 UA UAA200708557A patent/UA87548C2/ru unknown
- 2005-01-27 MX MX2007009059A patent/MX2007009059A/es active IP Right Grant
- 2005-01-27 CN CN2005800472656A patent/CN101189252B/zh not_active Expired - Fee Related
- 2005-01-27 EP EP11001502A patent/EP2402366A1/en not_active Withdrawn
- 2005-01-27 RS RS20120359A patent/RS52427B/en unknown
- 2005-01-27 CA CA002593801A patent/CA2593801A1/en not_active Abandoned
- 2005-01-27 NZ NZ556368A patent/NZ556368A/en not_active IP Right Cessation
- 2005-01-27 AU AU2005326149A patent/AU2005326149C1/en not_active Ceased
- 2005-01-27 SI SI200531553T patent/SI1848731T1/sl unknown
- 2005-01-27 PL PL05712250T patent/PL1848731T3/pl unknown
- 2005-01-27 KR KR1020077017177A patent/KR100896826B1/ko not_active IP Right Cessation
- 2005-01-27 JP JP2007553072A patent/JP4191238B2/ja not_active Expired - Fee Related
- 2005-01-27 EP EP05712250A patent/EP1848731B1/en active Active
- 2005-01-27 DK DK05712250.9T patent/DK1848731T3/da active
- 2005-01-27 BR BRPI0519942-5A patent/BRPI0519942A2/pt not_active IP Right Cessation
- 2005-01-27 WO PCT/US2005/002733 patent/WO2006080920A1/en active Application Filing
- 2005-01-27 PT PT05712250T patent/PT1848731E/pt unknown
-
2007
- 2007-07-03 IL IL184377A patent/IL184377A0/en unknown
- 2007-07-05 NO NO20073490A patent/NO20073490L/no not_active Application Discontinuation
- 2007-07-05 ZA ZA200705495A patent/ZA200705495B/xx unknown
- 2007-07-24 TN TNP2007000286A patent/TNSN07286A1/fr unknown
- 2007-07-26 MA MA30106A patent/MA29237B1/fr unknown
-
2012
- 2012-08-02 HR HRP20120634TT patent/HRP20120634T1/hr unknown
- 2012-08-13 CY CY20121100727T patent/CY1113030T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20073490L (no) | Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav | |
Römling et al. | Biofilm infections, their resilience to therapy and innovative treatment strategies | |
Giacometti et al. | In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics | |
BRPI0513903A (pt) | derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos | |
JP2012513467A5 (no) | ||
MXPA06000691A (es) | Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas. | |
EA201070504A1 (ru) | КАРБАЦЕФЕМ β-ЛАКТАМОВЫЕ АНТИБИОТИКИ | |
Wu et al. | Antisense yycG regulation of antibiotic sensitivity of methicillin-resistant Staphylococcus aureus in chronic osteomyelitis | |
AR073917A1 (es) | Sinergismo antibiotico | |
Qi et al. | Pharmacodynamics of linezolid-plus-fosfomycin against vancomycin-susceptible and-resistant Enterococci in vitro and in vivo of a galleria mellonella larval infection model | |
NO20073491L (no) | Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav | |
Gopinath et al. | Antimicrobial activity of actinomycetes isolated from coal mine soils of godavari belt region, AP, India | |
WO2010030811A3 (en) | CARBACEPHEM β-LACTAM ANTIBIOTICS | |
Koyama et al. | New structural scaffold 14-membered macrocyclic lactone ring for selective inhibitors of cell wall peptidoglycan biosynthesis in Staphylococcus aureus | |
NZ599175A (en) | Antibiotic compounds | |
Darabpour et al. | Isolation of an antibiotic producer Pseudomonas sp. from the Persian Gulf | |
WO2004098500A3 (en) | CARBACEPHEM ss-LACTAM ANTIBIOTICS | |
WO2007127218A3 (en) | Streptomyces-derived antimicrobial compound and method of using same against antibiotic-resistant bacteria | |
Mar Soe et al. | Ethyl gallate as a combination drug can overcome resistance in MRSA | |
CY1113157T1 (el) | Αντιβιοτικο 107891, παραγοντες του, φαρμακευτικως αποδεκτα αλατα και συνθεσεις και η χρηση τους | |
WO2010012381A8 (en) | Streptospirole derivatives | |
Sader et al. | In vitro activity and potency of the novel oxazolidinone MRX-I tested against contemporary clinical isolates of Gram-positive bacteria | |
NO20042181L (no) | Antibiotiske GE 81112-faktorer A, B, B1, farmasoytisk akseptable salter og sammensetninger samt anvendelse derav | |
MY148891A (en) | Novel antibiotic, bispolides a1, a2 and a3, and process for poducing the same | |
Churkina et al. | Peculiarities of antibiotic batumin action on biofilm formation by Staphylococcus aureus and Pseudomonas batumici |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |